Listen to this page using ReadSpeaker

Ben Shaberman

As the Foundation Fighting Blindness’ Director, Science Communications, Ben writes science and research articles for the Foundation’s website, newsletters and Eye on the Cure blog. Before joining the Foundation in 2003, he worked as a staff writer for health, long-term care and hospice care organizations. Ben’s freelance essays and commentaries have been published by a variety of national newspapers and magazines.

The following articles were authored by Ben Shaberman

Retinal Regeneration: Releasing Your Inner Salamander

Audio version:

For someone with a retinal disease such as retinitis pigmentosa or macular degeneration, their vision loss is caused by photoreceptor degeneration. Photoreceptors are the retinal cells that capture light and convert it into electrical signals, which are sent back to the brain where they are used to create the images we see.
Continue Reading…

Watch VISIONS 2018 LIVE on June 22 & 23

Get the inside scoop on this year’s top research advances and what’s next in retinal disease science by watching VISIONS 2018 LIVE!

We will be streaming several of our annual VISIONS conference sessions live on Friday, June 22 and Saturday, June 23. The sessions will be live streamed here on our blog, and our national Facebook as well.

Here’s the full schedule of live sessions:

Friday, June 22, 2018

  • 9:00 a.m. PDT – 10:15 a.m. PDT– Opening Session: Mission Possible! The Year’s Top Advances and What’s Next in Retinal Disease Science
  • 12:30 p.m. PDT – 2:00 p.m. PDT – Keynote Luncheon: Think Outside our Perceived Limitations
  • 3:10 p.m. PDT – 4:15 p.m. PDT – What You Need to Know About Genetics, Genetic Testing, and Patient Registries
  • 4:20 p.m. PDT – 5:25 p.m. PDT – Clinical Trials Update and Is a Clinical Trial Right for You?

Saturday, June 23, 2018

  • 9:00 a.m. PDT – 10:25 a.m. PDT – Retinitis Pigmentosa (RP) Research and Clinical Updates
  • 10:30 a.m. PDT – 11:40 a.m. PDT– Stress Management and Self-Care for People with Degenerative Diseases
  • 1:00 p.m. PDT – 2:35 p.m. PDT – Adapting and Thriving: Find Your Product – Tips and Tools for Peak Personal Performance
  • 3:05 p.m. PDT – 4:30 p.m. PDT – Closing Session: Featuring Biotech Executive Emmett Cunningham and Chapter Awards

The full list of the many sessions that will be live on the blog, with additional details, is also on our website here.

We hope you’ll tune in, share it with your friends, and learn more about the promising new advances in retinal research.

 

French Gene Therapy Company Advancing Three Programs for Retinal Diseases

Audio version:

Horama, a French biotech developing gene therapies for rare eye diseases, was established in 2014 as a spin-off of INSERM, France’s public scientific and technology institute. Today, the company has three gene-therapy development programs underway for rare inherited retinal diseases, targeting people with mutations in the genes PDE6B, RPE65, and RLBP1.
Continue Reading…

ARVO 2018: Dr. Henry Klassen Provides Update on jCyte Stem Cell Trials

Dr. Henry Klassen, jCyte co-founder and investigator at UC Irvine, provides an update in the video below on the clinical trials for an RP therapy derived from stem cells.

ARVO 2018: Port Delivery System Designed to Reduce Burden of Lucentis Injections for Wet AMD

Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial.

The image on the right shows the port implanted into an eye.

ARVO 2018: Dr. Stephen Daiger Reports on the State of Genetic Testing for Inherited Retinal Diseases

After presenting a poster on a new mutation in the RP gene KIF3B at the ARVO meeting in Honolulu, FFB-funded geneticist Dr. Stephen Daiger discusses the progress that’s been made in genetic testing for people with inherited retinal conditions.

ARVO 2018: Dr. Steve Rose Reports on CRISPR/Cas9 for Inherited Retinal Diseases

FFB’s own Dr. Steve Rose, chief scientific officer, reviews our commitment to funding and exploring CRISPR/Cas9 gene editing for inherited retinal disease in the video below.

FFB currently funds CRISPR/Cas9 projects at four institutions:

  • Johns Hopkins University (retinitis pigmentosa caused by the P23H mutation in RHO)
  • Columbia University (RP caused by the D190N mutation in RHO)
  • Massachusetts Eye and Ear Infirmary (RP caused by a mutation in RP1)
  • UCLA (Usher syndrome 1B caused by a mutation in MYO7A)

Want to learn more about the benefits of CRISPR/Cas9? Check out: A Cut-and-Paste Approach to Fixing Retinal-Disease Genes

ARVO 2018: Studies Show Mediterranean Diet May Lower Advanced AMD Risk

Audio version:

Several research studies have suggested that the Mediterranean diet (MeDi) – which is rich in fruits, vegetables, legumes, cereals, and fish – may be good for your health, including lowering your risk of an early visit from the grim reaper.

Known as the EYE-RISK CONSORTIUM, a large international research collaboration found that the MeDi reduced the risk of advanced age-related macular degeneration (AMD) by 39 percent. The researcher’s findings were highlighted in a poster on May 1 at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu.
Continue Reading…

Study Suggests Vitamin A May Benefit Children with RP

Audio version:

An FFB-funded study at Massachusetts Eye and Ear Infirmary (MEEI) suggests that vitamin A palmitate supplementation may slow the decline of cone function by nearly 50 percent in children with retinitis pigmentosa (RP). Cones are the photoreceptors that normally provide daytime vision, and the ability to read, recognize faces, and perceive colors. Cone function was evaluated in the study by a full-field electroretinogram or ERG, which measures the retina’s electrical response to light.
Continue Reading…

jCyte Reports Results for Phase 1/2a Clinical Trial for Retinal-Cell Treatment

jcyteA retinal-cell treatment for people with retinitis pigmentosa (RP) has performed encouragingly in a Phase 1/2a clinical trial. Developed by jCyte, the treatment was evaluated for 12 months in 28 people at two sites in Southern California.

Side effects were minor in the safety-oriented trial. Those receiving the highest dose of the treatment had the best results. Their visual acuity, as measured using an eye chart, was nearly two lines (nine letters) better in their treated eye than in their untreated eye. Some participants reported increased light sensitivity, improved color vision, better mobility, and improved reading ability. Ultimately, 22 of the 28 participants had their second eye treated. Continue Reading…